Application of structural biology tools in the study of viral hepatitis and the design of antiviral therapy

Gastroenterology

Volumn 123, Issue 4, 2002, Pages 1350-1363

  Yao, Nanhua ^a   Hong, Zhi ^a   Lau, Johnson Y N ^a  

^a Ribapharm Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; FAMCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIBAVIRIN; THYMIDINE TRIPHOSPHATE; UNCLASSIFIED DRUG; US 6187905; VIRUS PROTEIN; WO 00009543; WO 01 77113 A2; WO 0102424; WO 9950230;

BIOLOGICAL MODEL; DRUG DESIGN; DRUG STRUCTURE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VIRUS MORPHOLOGY; X RAY CRYSTALLOGRAPHY;

EID: 0036787460     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.36004     Document Type: Article

References (114)

1. Sweet RM. Introduction to crystallography. Methods Enzymol 1985;114:19-46.
2. Russell RB, Eggleston DS. New roles for structure in biology and drug discovery. Nat Struct Biol 2000;7(suppl):928-930.
3. Taremi SS, Beyer B, Maher M, Yao N, Prosise W, Weber PC, Malcolm BA. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci 1998;7:2143-2149.
4. Ferrari E, Wright-Minogue J, Fang JW, Baroudy BM, Lau JY, Hong Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coll. J Virol 1999;73: 1649-1654.
5. Abola E, Kuhn P, Earnest T, Stevens RC. Automation of x-ray crystallography. Nat Struct Biol 2000;7(suppl):973-977.
6. Burley SK. An overview of structural genomics. Nat Struct Biol 2000;7(suppl):932-934.
7. Edwards AM, Arrowsmith CH, Christendat D, Dharamsi A, Friesen JD, Greenblatt JF, Vedadi M. Protein production: feeding the crystallographers and NMR spectroscopists. Nat Struct Biol 2000;7(suppl):970-972.
8. Lamzin VS, Perrakis A. Current state of automated crystallographic data analysis. Nat Struct Biol 2000;7(suppl):978-981.
9. McPherson A, Malkin AJ, Kuznetsov YG. The science of macromolecular crystallization. Structure 1995;3:759-768.
10. Sweet RM. The technology that enables synchrotron structural biology. Nat Struct Biol 1998;5(suppl):654-656.
11. Hendrickson WA, Horton JR, LeMaster DM. Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure. EMBO J 1990;9:1665-1672.
12. Yang W, Hendrickson WA, Crouch RJ, Satow Y. Structure of ribonuclease H phased at 2 Å resolution by MAD analysis of the selenomethionyl protein. Science 1990;249:1398-1405.
13. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998;54:905-921.
14. Brunger AT, Laue ED. New approaches to study macromolecular structure and function. Curr Opin Struct Biol 2000;10:557.
15. Pflugrath JW. The finer things in X-ray diffraction data collection. Acta Crystallogr D Biol Crystallogr 1999;55:1718-1725.
16. Brunger AT, Adams PD, Rice LM. New applications of simulated annealing in X-ray crystallography and solution NMR. Structure 1997;5:325-336.
17. Palmer AG 3rd. Probing molecular motion by NMR. Curr Opin Struct Biol 1997;7:732-737.
18. 13C chemical-shift index: a simple method for the identification of protein secondary structure using 13C chemical-shift data. J Biomol NMR 1994;4:171-180.
19. Cornilescu G, Delaglio F, Bax A. Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR 1999;13:289-302.
20. Fetrow JS, Skolnick J. Method for prediction of protein function from sequence using the sequence-to-structure-to-function paradigm with application to glutaredoxins/thioredoxins and T1 ribonucleases. J Mol Biol 1998;281:949-968.
21. Zhang B, Rychlewski L, Pawlowski K, Fetrow JS, Skolnick J, Godzik A. From fold predictions to function predictions: automation of functional site conservation analysis for functional genome predictions. Protein Sci 1999;8:1104-1115.
22. Montelione GT, Anderson S. Structural genomics: keystone for a Human Proteome Project. Nat Struct Biol 1999;6:11-12.
23. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996; 274:1531-1534.
24. Philippopoulos M, Mandel AM, Palmer AG 3rd, Lim C. Accuracy and precision of NMR relaxation experiments and MD simulations for characterizing protein dynamics. Proteins 1997;28: 481-493.
25. Kay LE, Gardner KH. Solution NMR spectroscopy beyond 25 kDa. Curr Opin Struct Biol 1997;7:722-731.
26. Wuthrich K. The second decade-into the third millenium. Nat Struct Biol 1998;5(suppl):492-495.
27. Wider G, Wuthrich K. NMR spectroscopy of large molecules and multimolecular assemblies in solution. Curr Opin Struct Biol 1999;9:594-601.
28. Riek R, Pervushin K, Wuthrich K. TROSY and CRINEPT: NMR with large molecular and supramolecular structures in solution. Trends Biochem Sci 2000;25:462-468.
29. Gardner KH, Kay LE. The use of 2H, 13C, 15N multidimensional NMR to study the structure and dynamics of proteins. Annu Rev Biophys Biomol Struct 1998;27:357-406.
30. Browne WJ, North AC, Phillips DC, Brew K, Vanaman TC, Hill RL. A possible three-dimensional structure of bovine alpha-lactalbumin based on that of hen's egg-white lysozyme. J Mol Biol 1969;42:65-86.
31. Warme PK, Scheraga HA. Refinement of the x-ray structure of lysozyme by complete energy minimization. Biochemistry 1974; 13:757-767.
32. Sali A, Potterton L, Yuan F, van Vlijmen H, Karplus M. Evaluation of comparative protein modeling by MODELLER. Proteins 1995; 23:318-326.
33. Thornton JM, Todd AE, Milburn D, Borkakoti N, Orengo CA. From structure to function: approaches and limitations. Nat Struct Biol 2000;7(suppl):991-994.
34. Sanchez R, Sali A. Comparative protein structure modeling. Introduction and practical examples with modeller. Methods Mol Biol 2000;143:97-129.
35. Blundell TL, Sibanda BL, Sternberg MJ, Thornton JM. Knowledge-based prediction of protein structures and the design of novel molecules. Nature 1987;326:347-352.
36. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000;29:291-325.
37. Neubig RR, Thomsen WJ. How does a key fit a flexible lock? Structure and dynamics in receptor function. Bioessays 1989; 11:136-141.
38. Gait MJ, Karn J. Progress in anti-HIV structure-based drug design. Trends Biotechnol 1995;13:430-438.
39. Wade RC. 'Flu' and structure-based drug design. Structure 1997;5:1139-1145.
40. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000;118: S83-103.
41. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000;61:362-366.
42. Zavaglia C, Airoldi A, Pinzello G. Antiviral therapy of HBV- and HCV-induced liver cirrhosis. J Clin Gastroenterol 2000;30:234-241.
43. Hong JH, Choi Y, Chun BK, Lee K, Chu CK. Current status of anti-HBV chemotherapy. Arch Pharm Res 1998;21:89-105.
44. Hoofnagle JH. Therapy of viral hepatitis. Digestion 1998;59: 563-578.
45. Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999;58:101-141.
46. Deres K, Rubsamen-Waigmann H. Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV. Infection 1999;27:S45-51.
47. Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000;31:219-224.
48. Sarafianos SG, Das K, Clark AD Jr, Ding J, Boyer PL, Hughes SH, Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci U S A 1999;96:10027-10032.
49. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75:4771-4779.
50. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27: 1670-1677.
51. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-455.
52. Cohen J. The scientific challenge of hepatitis C. Science 1999; 285:26-30.
53. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500.
54. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
55. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier Ge, Bonino F, Colombo M, Lee W-S, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-364.
56. Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, Andoh T, Yoshida I, Okayama H. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991;65:1105-1113.
57. Heinz FX. Comparative molecular biology of flaviviruses and hepatitis C virus. Arch Virol Suppl 1992;4:163-171.
58. Mizokami M, and Ohba K. Molecular classification of hepatitis C virus. Gastroenterol Jpn 1993;28(suppl 5):42-44.
59. Ohba K, Mizokami M, Lau JY, Orito E, Ikeo K, Gojobori T. Evolutionary relationship of hepatitis C, pesti-, flavi-, plantviruses, and newly discovered GB hepatitis agents. FEBS Lett 1996;378:232-234.
60. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 1994;75:1053-1061.
61. van Doorn LJ. Review: molecular biology of the hepatitis C virus. J Med Virol 1994;43:345-356.
62. Lohmann V, Koch JO, Bartenschlager R. Processing pathways of the hepatitis C virus proteins. J Hepatol 1996;24:11-19.
63. Simmonds P. Virology of hepatitis C virus. Clin Ther 1996;18: 9-36.
64. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993;67:1385-1395.
65. Shimotohno K, Tanji Y, Hirowatari Y, Komoda Y, Kato N, Hijikata M. Processing of the hepatitis C virus precursor protein. J Hepatol. 1995;22:87-92.
66. Gorbalenya AE, Koonin EV, Donchenko AP, Blinov VM. A novel superfamily of nucleoside triphosphate-binding motif containing proteins which are probably involved in duplex unwinding in DNA and RNA replication and recombination. FEBS Lett 1988;235: 16-24.
67. Koonin EV, Dolja VV. Evolution and taxonomy of positive-strand RNA viruses: implications of comparative analysis of amino acid sequences. Crit Rev Biochem Mol Biol 1993;28:375-430.
68. Korolev S, Yao N, Lohman TM, Weber PC, Waksman G. Comparisons between the structures of HCV and Rep helicases reveal structural similarities between SF1 and SF2 super-families of helicases. Protein Sci 1998;7:605-610.
69. Gross CH, Shuman S. Vaccinia virions lacking the RNA helicase nucleoside triphosphate phosphohydrolase II are defective in early transcription. J Virol 1996;70:8549-8557.
70. Fernandez A, Guo HS, Saenz P, Simon-Buela L, Gomez de Cedron M, Garcia JA. The motif V of plum pox potyvirus Cl, RNA helicase is involved in NTP hydrolysis and is essential for virus RNA replication. Nucleic Acids Res 1997;25:4474-4480.
71. Gross CH, Shuman S. The nucleoside triphosphatase and helicase activities of vaccinia virus NPH-II are essential for virus replication. J Virol 1998;72:4729-4736.
72. Kolykhalov AA, Mihalik K, Feinstone SM, Rice CM. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ in vivo. J Virol 2000;74:2046-2051.
73. Suzich JA, Tamura JK, Palmer-Hill F, Warrener P, Grakoui A, Rice CM, Feinstone SM, Collett MS. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol 1993;67:6152-6158.
74. Kim DW, Gwack Y, Han JH, Choe J. Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein. Virus Res 1997;49:17-25.
75. Behrens S-E, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996;15:12-22.
76. Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997;71:8416-8428.
77. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-87.
78. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, The Hepatitis Interventional Therapy Group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatol 2001;34:395-403.
79. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
80. Turner BG, Summers MF. Structural biology of HIV. J Mol Biol 1999;285:1-32.
81. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-355.
82. Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996;87:331-342.
83. Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, Tomei L, De Francesco R, Kuo LC, Chen Z. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 1998;7:837-847.
84. Yao N, Hesson T, Cable M, Hong Z, Kwong AD, Le HV, Weber PC. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997;4:463-467.
85. Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C, Caron PR. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 1998;6: 89-100.
86. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure Fold Des 1999;7:1353-1363.
87. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure Fold Des 1999;7:1417-1426.
88. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 1999;96:13034-13039.
89. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999;6:937-943.
90. Bressanelli S, Tomei L, Rey FA, De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol 2002;76:3482-3492.
91. Spahn CM, Kieft JS, Grassucci RA, Penczek PA, Zhou K, Doudna JA, Frank J. Hepatitis C virus IRES RNA-induced changes in the conformation of the 40s ribosomal subunit. Science 2001;291: 1959-1962.
92. Klinck R, Westhof E, Walker S, Afshar M, Collier A, Aboul-Ela F. A potential RNA drug target in the hepatitis C virus internal ribosomal entry site. Rna 2000;6:1423-1431.
93. Lukavsky PJ, Otto GA, Lancaster AM, Sarnow P, Puglisi JD. Structures of two RNA domains essential for hepatitis C virus internal ribosome entry site function. Nat Struct Biol 2000;7: 1105-1110.
94. Butkiewicz NJ, Yao N, Wright-Minogue J, Zhang R, Ramanathan L, Lau JY, Hong Z, Dasmahapatra B. Hepatitis C NS3 protease: restoration of NS4A cofactor activity by N-biotinylation of mutated NS4A using synthetic peptides. Biochem Biophys Res Commun 2000;267:278-282.
95. Wright-Minogue J, Yao N, Zhang R, Butkiewicz NJ, Baroudy BM, Lau JY, Hong Z. Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors. J Hepatol 2000;32:497-504.
96. Cho HS, Ha NC, Kang LW, Chung KM, Back SH, Jang SK, Oh BH. Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA. J Biol Chem 1998;273:15045-15052.
97. Yao N, Weber PC. Helicase, a target for novel inhibitors of hepatitis C virus. Antivir Ther 1998;3:93-97.
98. de la Cruz J, Kressler D, Linder P. Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families. Trends Biochem Sci 1999;24:192-198.
99. Kadare G, Haenni AL. Virus-encoded RNA helicases. J Virol 1997;71:2583-2590.
100. Bork P, Koonin EV. An expanding family of helicases within the 'DEAD/H' superfamily. Nucleic Acids Res 1993;21:751-752.
101. Pause A, Methot N, Sonenberg N. The HRIGRXXR region of the DEAD box RNA helicase eukaryotic translation initiation factor 4A is required for RNA binding and ATP hydrolysis. Mol Cell Biol 1993;13:6789-6798.
102. Hong Z, Cameron CE, Walker MP, Castro C, Yao N, Lau JY, Zhong W. A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 2001;285:6-11.
103. Llinas-Brunet M, Bailey M, Deziel R, Fazal G, Gorys V, Goulet S, Halmos T, Maurice R, Poirier M, Poupart MA, Rancourt J, Thibeault D, Wernic D, Lamarre D, Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 1998;8:2719-2724.
104. Llinas-Brunet M, Bailey M, Fazal G, Goulet S, Halmos T, Laplante S, Maurice R, Poirier M, Poupart MA, Thibeault D, Wernic D, Lamarre D. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg Med Chem Lett 1998;8:1713-1718.
105. Steinkuhler C, Biasiol G, Brunetti M, Urbani A, Koch U, Cortese R, Pessi A, De Francesco R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998;37:8899-8905.
106. Ingallinella P, Altamura S, Bianchi E, Taliani M, Ingenito R, Cortese R, De Francesco R, Steinkuhler C, Pessi A. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 1998;37:8906-8914.
107. Cicero DO, Barbato G, Koch U, Ingallinella P, Bianchi E, Nardi MC, Steinkuhler C, Cortese R, Matassa V, De Francesco R, Pessi A, Bazzo R. Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies. J Mol Biol 1999;289:385-396.
108. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
109. Chen KX, Arasappan A, Venkatraman S, Parekh TN, Gu H, Njoroge FG, Girijavallabhan VM, Ganguly A, Saksena AK, Jao E, Yao N, Prongay AJ, Madison VS, Vibulbhan B. Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties. WO 01/77113 A2, 2001.
110. Arasappan A, Parekh TN, Njoroge FG, Girijavallabhan VM, Ganguly A. Novel Imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus. WO 02/08198 A2, 2001.
111. Tung RD, Farmer LJ, Bhisetti GR, Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. WO 99/50230, 1999.
112. Perni R, Court J, O'Malley E, Bhisetti GR. Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. WO 01/74768 A2, 2001.
113. Llinas-Brunet M, Bailey MD, Cameron DR, Faucher A-M, Ghiro E, Goudreau N, Halmos T, Poupart M-A, Rancourt J, Tsantrizos YS, Wernic DM, Simoneau B. Hepatitis C inhibitor tri-peptides. WO 00/09543, 2000.
114. Tsantrizos YS, Cameron DR, Faucher A-M, Ghiro E, Goudreau N, Halmos T, Llinas-Brunet M. Macrocyclic Peptides active against the hepatitis C virus. WO 00/59929, 2000.